Cue Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cue Biopharma, Inc. | ||
| Dated: March 16, 2026 | By: | /s/ Usman Azam |
|---|---|---|
| Usman AzamPresident, Chief Executive Officer and Director(Principal Executive Officer) | ||
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Cue Biopharma, Inc., hereby severally constitute and appoint Usman Azam and Lucinda Warren, our true and lawful attorneys, with full power to him or her to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable Cue Biopharma, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ Usman Azam | President, Chief Executive Officer and Director | March 16, 2026 |
| Usman Azam | (Principal Executive Officer) | |
| /s/ Lucinda Warren | Chief Financial and Business Officer | March 16, 2026 |
| Lucinda Warren | (Principal Financial and Accounting Officer) | |
| /s/ Peter A. Kiener | Director | March 16, 2026 |
| Peter A. Kiener | ||
| /s/ Jill Marie Broadfoot | Director | March 16, 2026 |
|---|---|---|
| Jill Marie Broadfoot | ||
| /s/ Pamela Garzone | Director | March 16, 2026 |
|---|---|---|
| Pamela Garzone | ||
| /s/ Patrick Verheyen | Director | March 16, 2026 |
| Patrick Verheyen | ||
| /s/ Frank Morich | Director | March 16, 2026 |
| Frank Morich | ||
| /s/ Pasha Sarraf | Director | March 16, 2026 |
| Pasha Sarraf | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.